Abstract: Process for preparing a heat-treated pooled human platelet lysate, said process comprising the steps of: a) Providing a pooled human platelet lysate (p HPL), b) Heat-treating the pooled human platelet lysate at a temperature of 50° C. to 70° C. during 20 to 40 minutes, c) Purifying the heat-treated pooled human platelet lysate of step b).

Abstract: The present invention relates to methods for detecting a target in a sample using mutated nanobodies, wherein an amino acid present in the loop of the FR1 region of framework of the nanobodies is mutated to cysteine.

Abstract: The present invention relates on a process for preparing platelet lysate fraction, said process comprising the steps of: 1) providing a platelet lysate, 2) collecting from said platelet lysate a fraction wherein the components exhibit a maximum molecular weight of 100 kDa, on a specific platelet lysate fraction and its use as a drug.

Abstract: Process for preparing a heat-treated pooled human platelet lysate, said process comprising the steps of: a) Providing a pooled human platelet lysate (p HPL), b) Heat-treating the pooled human platelet lysate at a temperature of 50° C. to 70° C. during 20 to 40 minutes, c) Purifying the heat-treated pooled human platelet lysate of step b).

Abstract: A process for preparing a modified heat-treated platelet pellet lysate, said process comprising the steps of: a) Providing a platelet pellet lysate, b) Heat-treating the platelet pellet lysate at a temperature of 55° C. to 65° C. during 20 to 40 minutes, c) Purifying the heat-treated platelet pellet lysate of step b) so as to obtain a modified heat treated platelet pellet lysate having a total protein content of less than 70% of the total protein content of the platelet pellet lysate of step a).

Abstract: The present invention is directed to pharmaceutical solution comprising at least dopamine for use in treating Parkinson's disease, wherein said pharmaceutical solution is kept under anaerobic conditions from its formulation to its administration.

Abstract: The present invention is directed to pharmaceutical solution comprising at least dopamine for use in treating Parkinson's disease, wherein said pharmaceutical solution is kept under anaerobic conditions from its formulation to its administration.

Abstract: The present invention is directed to pharmaceutical solution comprising at least dopamine for use in treating Parkinson's disease, wherein said pharmaceutical solution is kept under anaerobic conditions from its firmation to its administration.

Abstract: A modular green roof system includes: a bottom layer including a porous structure such that water may pass through the bottom layer; a silt management layer adjacent to the bottom layer; an insulation layer adjacent to the silt management layer; a water retention layer adjacent to the insulation layer, a growth media layer adjacent to the water retention layer; a biodegradable layer including plant seed adjacent to the growth media layer; a top layer including a porous structure such that water and sunlight may pass through the top layer, wherein the top layer and the bottom layer form a perimeter within which the silt management layer, the water retention layer, the growth media layer and the biodegradable layer are contained; and a plurality of thickness controllers spaced intermittently such that the distance between the bottom layer and the top layer is limited by the thickness controllers.